Johns Hopkins POC-IT: Point of Care Information Technology [Home]
HIV Guide
 Zambia HIV National Guidelines
 


Introduction  

HIV Counseling and Testing  

Sexually Transmitted Infections (STIs)  

General Principles of Antiretroviral Therapy for Chronic HIV Infection in Adults and Adolescents  

When to Start ARV Therapy for Chronic HIV Infection in Adults and Adolescents  

Initial Regimen for ARV Therapy  

Adherence  

Baseline evaluation and Monitoring  

Calculations: Ideal Body Weight, Body Mass Index and Creatinine Clearance  

ARV Therapy for Individuals with Tuberculosis Co-Infection  

Adverse Effects and Toxicity  

Immune Reconstitution Inflammatory Syndrome (IRIS)  

Changing or Stopping ART  

Treatment Failure  

Stopping ARV Therapy  

Post Exposure Prophylaxis  

Cotrimoxazole Prophylaxis  

WHO Staging in Adults and Adolescents  

Nutrition Care and Support  

Palliative Care in HIV and AIDS  

 Guide Editors
 Editor In Chief
    Joel E. Gallant, MD, MPH

Pharmacology Editor
    Paul Pham, PharmD, BCPS

Zambia Guideline Team
   Peter Mwaba MMed PhD FRCP
   Alywn Mwinga MMed
   Isaac Zulu MMed MPH
   Velepie Mtonga MMed
   Albert Mwango MBChB
   Jabbin Mulwanda MMed FCS
 

 

 

Diagnosis>Organ System>
Home Page

Aphthous ulcers

Spyridon Marinopoulos, M.D.
04-24-2009

  • Apthous ulcers is a ubiquitous illness and considered prevalent in Zambia.
  • Little known about specific epidemiology of apthous ulcers in Zambia.   
  • Dx and management of apthous ulcers in Zambia is largely similar to that in developed world.
  • Ability to perform diagnostic Bx for persistent, atypical, and non-healing ulcers is more limited in Zambia; empiric therapies for other potential etiologies may be reasonable management option.
  • Thalidomide not widely available in Zambia.
Zambia Information Author: Larry William Chang, MD, MPH

PATHOGENS

  • None (idiopathic).
  • See DDx below for other conditions causing oral ulcers.

CLINICAL

  • Common oral lesions classified by size and duration into minor, major and herpetiform.
  • Minor: Small (<5 mm) single or multiple tender ulcerations, persist x7-14 d. Exam: superficial erosions w/ fibrinous covering often surrounded by red halo. Involve mobile mucosa (tongue, floor of mouth, soft palate and buccal/labial mucosa).
  • Major: larger painful ulcerations, persist for up to 6 wks, eventually heal w/ scar formation.
  • Herpetiform: crops of small ulcers that eventually coalesce; may be mistaken for HSV by appearance.
  • In HIV-infected individuals, tend to occur more frequently, last longer and may be more painful. Can significantly effect nutritional health in an already at risk population.
  • DDx: viral (HSV, CMV, Coxsackie), fungal (Histoplasma, Cryptococcus, Cryptosporidium, Mucor), bacterial (TB, syphilis), neoplasm (NHL, KS, squamous cell Ca), Behcet's disease, Reiter's syndrome, SLE, bullous pemphigoid, pemphigus vulgaris, dermatitis herpetiformis, Crohn's disease, celiac sprue, pernicious anemia, Sweet syndrome.
  • Predisposing factors: Family history, stress (emotional/physical), iron or vitamin deficiencies (folic acid, vitamin B12), allergies, hormonal changes, diet/food hypersensitivity, trauma, immune dysfunction, cyclic neutropenia, sodium lauryl sulfate (toothpaste detergent), celiac sprue, inflammatory bowel disease, pernicious anemia , drugs (NSAIDs, alendronate, nicorandil).

DIAGNOSIS

  • Clinical presentation & lesion appearance important. Initial Rx trial w/ topical agents helpful diagnostically. Bx +/- Cx for persistent, atypical appearing ulcerations.
  • Oral mucosal Bx required for atypical or non-healing ulcers to exclude possibility of deep fungal infection, viral infection and neoplasms.
  • CBC, iron studies, RBC folate, vitamin B12, serum antiendomysial/transglutaminase antibody.
  • Consider other etiologies (infectious): HSV: Tzank smear w/ inclusion-bearing giant cells; CMV: multinucleated giant cells; Syphilis: +RPR/FTA; Cryptosporidiosis, mucormycosis, histoplasmosis: +Bx/Cx.
  • Consider other etiologies (noninfectious): Behcet's syndrome: genital ulcers, uveitis, retinitis. Reiter's syndrome: uveitis, conjunctivitis, arthritis, HLA B27+. Crohn's: bloody diarrhea, mucus, GI ulcerations. SLE: malar rash, +ANA. Cyclic neutropenia: periodic fever & neutropenia. Squamous cell CA: +Bx, +LN. Bullous pemphigoid/pemphigus vulgaris: diffuse skin involvement.

TREATMENT

GENERAL PRINCIPLES

  • Recommendations represent author's opinion.
  • Treatments discussed below apply to idiopathic aphthous ulcers only. Treat underlying condition if present.
  • Aphthous ulcers in conjunction w/ Sx of uveitis, conjunctivitis, arthritis, diarrhea, genital ulcerations or other systemic manifestation should prompt search for systemic autoimmune or inflammatory condition.
  • Topical corticosteroids are 1st line Rx: reduce ulcer duration and pain compared with controls, but no consistent effect on incidence of ulceration.
  • Reserve PO steroids and thalidomide for severe cases refractory to topical Rx.
  • Goals of Rx: promote ulcer healing, reduce pain, diminish frequency of recurrence while maintaining nutritional intake.
TOPICAL

  • Topical corticosteroids: 1st line Rx. Multiple agents can be used: Betamethasone, fluocinonide, fluocinolone, fluticasone, and clobetasol more effective than hydrocortisone & triamcinolone, but higher risk for adrenocortical suppression & predisposition to candidiasis.
  • Triamcinolone dental paste (Kenalog in Orabase) or fluocinonide dental paste (Lidex in Orabase): apply to ulcer 2-3 times daily x 5d or clobetasol propionate mouthwash 10 cc x 5 min swish & spit 3 times daily.
  • Dexamethasone elixir: 0.5 mg/5 cc swish & spit 3 times daily.
  • Amlexanox (Aphthasol 5%) paste: apply 1/4 inch (0.5 cm) topically to ulcer four times a day. Apply following oral hygiene and as soon as possible after noticing symptoms.
  • Chlorhexidine 15 cc oral rinse 0.12% swish & spit x 30 sec twice-daily: increases # of ulcer-free days and interval between ulcer development but does not affect incidence/severity of ulceration.
  • Tetracycline 250 mg capsule, dissolve in 180 cc water, swish & spit 4 times daily.
  • Viscous lidocaine 2%, apply to ulcer w/ cotton swab 4 times daily PRN.
  • Triamcinolone injection may be useful for persistent isolated lesions.
  • Mile's solution: 60 mg hydrocortisone, 20 cc mycostatin, 2 gm tetracycline, and 120 cc viscous lidocaine (swish & spit). The 2 active ingredients are HC and TCN, but clinical trials have used more potent topical steroids.
SYSTEMIC

  • Severe cases only: prednisone 60 mg PO once-daily x 5-7d, then D/C. Rx >7d requires slow taper. Avoid if possible in immunocompromised pts, including HIV.
  • Thalidomide 200 mg PO once-daily x 4 wks effective in 2/3 of pts w/ resistant aphthous ulcers. Some pts may require thalidomide maintenance dose (200 mg twice a wk).
  • Dapsone, colchicine and pentoxifylline have been reported as potentially effective in refractory cases, although randomized controlled trials are lacking.
MISCELLANEOUS

  • Brush atraumatically (use small-headed, soft toothbrush). Avoid hard/sharp foods/trauma to oral mucosa.
  • Correct iron & vitamin deficiencies.
  • Exclude potentially offending foods.
  • Consider allergy (patch) testing.
  • Suppress ovulation if menses/OCP association.
  • D/C potentially causal medications.

Drug Comments

DrugRecommendations/Comments
thalidomide Effective for refractory aphthous ulcers. Adverse effects include somnolence, rash, peripheral sensory neuropathy and teratogenic potential. Use with serious disease when topical therapy ineffective.

Basis for Recommendations

  • Jacobson JM, Greenspan JS, Spritzler J, et al.; Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.; N Engl J Med; 1997; Vol. 336; pp. 1487-93;
    ISSN: 0028-4793;
    PUBMED: 9154767
    Rating: Basis for recommendation
    Comments:Double-blind, randomized, placebo-controlled study of thalidomide as therapy for oral aphthous ulcers in HIV+ patients. Patients received 4-week course of either 200 mg of thalidomide or placebo PO once-daily. They were evaluated weekly for condition of the ulcers, quality of life, and evidence of toxicity. 55% in thalidomide group had complete healing of aphthous ulcers after 4 weeks vs. only 7% of pts in control group (P<0.001).

REFERENCES

REFERENCED WITHIN THIS GUIDE


 
Diagnosis
 


Complications of Therapy


Malignancies


Miscellaneous


Opportunistic Infections


Organ System

Drugs
 


Antimicrobial Agents


Antiretrovirals


Miscellaneous

Guidelines
 


Zambia HIV National Guidelines

Management
 


Antiretroviral Therapy


Laboratory Testing


Miscellaneous

Pathogens
 


Bacteria


Fungi


Parasites


Viruses

View All Modules
 
Index
 
 
Contacts    Help    Copyright    Acknowledgments    Abbreviations